Kobayashi Pharmaceutical Co., Ltd.
Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Kobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an audit and supervisory committee, subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, to strengthen its corporate governance framework.
Key Figures
- Scheduled Transition Date: March 27, 2026 (subject to Annual General Meeting approval)
- Transition Details: From a company with a board of auditors to a company with an audit and supervisory committee
- Background: Corporate governance reform based on recurrence prevention measures dated September 17, 2024
AI要約
Background and Purpose of the Transition
Kobayashi Pharmaceutical Co., Ltd. has decided to transition from a company with a board of auditors to a company with an audit and supervisory committee as part of the "Fundamental Reform of Corporate Governance" announced in the press release dated September 17, 2024 regarding measures to prevent recurrence. This aims to strengthen the supervisory functions of the Board of Directors and enhance management agility. Audit and supervisory committee members will be part of the Board of Directors to ensure clear separation between supervisory and executive functions.
Timing of the Transition and Future Measures
The transition to a company with an audit and supervisory committee is subject to approval at the Annual General Meeting of Shareholders scheduled for March 27, 2026. Details of executive appointments post-transition have already been disclosed separately in the "Notice Regarding Executive Appointments Following the Transition to a Company with an Audit and Supervisory Committee." Amendments to the Articles of Incorporation will be announced once finalized.
